Joincare Pharmaceutical Group Industry Co.,Ltd.

SHSE:600380 Voorraadrapport

Marktkapitalisatie: CN¥22.4b

Joincare Pharmaceutical Group IndustryLtd Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Xiong Yu

Algemeen directeur

CN¥3.6m

Totale compensatie

Percentage CEO-salaris72.2%
Dienstverband CEOno data
Eigendom CEOn/a
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

May 31
Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

Recent updates

Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market

Aug 13
Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market

We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease

Jun 23
We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease

Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

May 31
Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings

Apr 09
Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings

Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel

Mar 04
Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel

Analyse CEO-vergoeding

Hoe is Xiong Yu's beloning veranderd ten opzichte van Joincare Pharmaceutical Group IndustryLtd's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

CN¥1b

Jun 30 2024n/an/a

CN¥1b

Mar 31 2024n/an/a

CN¥1b

Dec 31 2023CN¥4mCN¥3m

CN¥1b

Sep 30 2023n/an/a

CN¥1b

Jun 30 2023n/an/a

CN¥2b

Mar 31 2023n/an/a

CN¥2b

Dec 31 2022CN¥4mCN¥3m

CN¥2b

Sep 30 2022n/an/a

CN¥1b

Jun 30 2022n/an/a

CN¥1b

Mar 31 2022n/an/a

CN¥1b

Dec 31 2021CN¥3mCN¥2m

CN¥1b

Compensatie versus markt: De totale vergoeding ($USD 502.77K ) Xiong } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de CN markt ($USD 210.86K ).

Compensatie versus inkomsten: De vergoeding van Xiong is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Xiong Yu (63 yo)

no data

Tenure

CN¥3,600,000

Compensatie

Mr. Xiong Yu served as Non-Executive Director of Livzon Pharmaceutical Group Inc. since June 30, 2020 until October 14, 2024. He serves as the Deputy Vice-President and a Researcher of China State Institut...